Feb 25, 2026 10:15 AM EST Emerging Growth Conference Keyword Search Year All20262025202420232022202120202019201820172016 Jun 17, 2026 MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum Jun 08, 2026 MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential Jun 04, 2026 MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference May 27, 2026 MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH May 20, 2026 MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH May 18, 2026 MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions May 14, 2026 MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update May 11, 2026 MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 Apr 10, 2026 MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity Mar 26, 2026 MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
Jun 17, 2026 MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
Jun 08, 2026 MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
Jun 04, 2026 MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
May 27, 2026 MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
May 20, 2026 MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
May 18, 2026 MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
May 11, 2026 MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
Apr 10, 2026 MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
